{"id":"anagre-cap","_chembl":{"chemblId":"CHEMBL4074922","moleculeType":"Small molecule","molecularWeight":"652.72"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Anagre Cap.","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:11:26.315380+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:11:39.221771+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:11:31.826199+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Anagre Cap.","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:11:32.302739+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4074922/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:11:33.197416+00:00"}},"_dailymed":null,"aiSummary":"Anagrelide, marketed by Yuhan Corporation, is an established drug in the market with a key composition patent expiring in 2028. Its primary strength lies in its current market presence and revenue generation, though specific figures are not disclosed. The primary risk is the potential increase in competition following the patent expiry in 2028.","_scrapedAt":"2026-03-28T00:27:12.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:11:39.221855+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT03232177","phase":"PHASE4","title":"Anagre Cap. in Patients With High-Risk Essential Thrombocythemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-06-05","conditions":"Essential Thrombocythemia","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL4074922"},"_approvalHistory":[],"publicationCount":61251,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anagre Cap.","genericName":"Anagre Cap.","companyName":"Yuhan Corporation","companyId":"yuhan-corporation","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:11:39.221855+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}